查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011317

动物生物技术市场：依产品类型、技术、应用和最终用户划分－2026-2032年全球预测

Animal Biotechnology Market by Product Type, Technology, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，动物生物技术市场价值将达到 338.1 亿美元，到 2026 年将成长至 364.9 亿美元，到 2032 年将达到 605.6 亿美元，复合年增长率为 8.68%。

主要市场统计数据
基准年 2025 338.1亿美元
预计年份：2026年 364.9亿美元
预测年份 2032 605.6亿美元
复合年增长率 (%) 8.68%

动物生物技术策略方法，将科学创新、监管发展和供应链韧性作为商业决策的核心驱动力。

动物生物技术正处于一个转折点，分子工具、生产平台和法规结构的进步相互交融，重新定义了动物健康、营养和研究解决方案的开发和应用方式。该产业如今涵盖重组蛋白、疫苗创新、精准饲料添加剂和诊断技术，不仅支持畜牧业生产力，也支持生物医学研究和转化科学。投资者、政策制定者和商业领袖越来越关注那些能够改善动物福利、建立具有韧性的价值链、加速研发週期并减少环境影响的技术。

技术变革、不断演变的商业化模式以及监管调整正在重塑动物生物技术领域的竞争动态。

动物生物技术领域正经历一场变革，其驱动力来自于平台技术的成熟和商业化路径的演进。基因编辑工具和基因改造调查方法正从概念验证（PoC）阶段迈向应用案例阶段，加速表型工程​​和疫苗抗原设计。同时，包括禽类、昆虫和哺乳动物平台在内的细胞培养系统的改进，使得生物製药生产更具规模化和成本效益，并减少了对传统製程的依赖。定序和诊断技术的进步也为这些技术变革提供了补充，次世代定序和改进的PCR工作流程提高了分析解析度并加快了结果出炉速度。

了解 2025 年关税变化将如何重塑整个动物生物技术价值链的供应链、筹资策略和营运风险框架。

2025年美国关税政策的发展正对动物生物技术领域的供应链经济、筹资策略和产业计画产生累积影响。试剂、实验室设备和特殊组件进口关税的提高推高了进口后的投入成本，挤压了製造商和服务供应商的利润空间。为应对这项挑战，企业正在加速供应商多元化，与美国以外的供应商签订长期合同，并探索近岸外包和回流生产等方案，以降低关税波动带来的风险。这些变化正在对采购週期、库存管理和资本配置决策产生后续影响。

详细的細項分析揭示了产品、技术、应用和最终用户方面的差异如何决定开发重点、市场模式和投资重点。

细分趋势揭示了每种产品类型、技术、应用和最终用户实现价值创造和业务优先事项的清晰路径。按产品类型划分，该领域涵盖重组蛋白和疫苗。重组蛋白包括抗体、酵素和生长激素，其中酵素的亚类包括脂肪酶、植酸酶和蛋白酶。另一方面，疫苗包括DNA疫苗、灭活疫苗、减毒活病毒疫苗和次单位疫苗。这种多样性要求采用差异化的开发策略。对于抗体而言，特异性和大规模生产是优先考虑的因素；对于酵素而言，热稳定性和与饲料的整合至关重要；而对于每种疫苗类型，都需要适当的低温运输和监管措施。

区域比较分析表明，美洲、欧洲、中东、非洲和亚太地区的趋势如何影响监管策略、製造和采用轨迹。

区域趋势影响着美洲、欧洲、中东和非洲以及亚太地区的机会范围、法律规范和应用轨迹。在美洲，完善的研究基础设施和大量的私人投资正在加速新型生物製药和诊断平台的快速应用，而物流中心和先进製造群则为合约开发和生产（CDMO）活动提供了支援。北美与监管机构的对话日益侧重于监管协调和创新治疗方法的快速核准流程，从而创造出积极主动的监管策略管理环境，进而实现更可预测的规模化和商业化。

如何透过垂直整合、平台差异化和人才优先等企业策略来决定动物生物技术领域的竞争地位。

动物生物技术领域的企业策略正趋于形成几种可重复的模式，这些模式预示着整体竞争格局中的赢家和输家。主要企业正寻求垂直整合和策略伙伴关係，以确保关键投入、缩短产品上市时间并拓展增值服务。合约研发生产机构（CDMO）正投资于平台柔软性，以适应重组蛋白和疫苗的生产模式，从而获得更广泛的外包研发和生产市场份额。同时，专业技术供应商正透过专有细胞株、优化的发酵製程或独特的定序和诊断化学技术来实现差异化，从而为特定终端用户提供性能优势。

为领导者提供切实可行的策略，以加强供应链、模组化製造、积极与监管机构互动，并加速基于平台的创新，以实现商业性扩充性。

行业领导者应采取一系列切实措施，将科学知识转化为永续的商业性优势。首先，透过认证多家地理位置分散的供应商、确保关键试剂的策略性库存缓衝以及投资供应链视觉化系统来分散采购和物流，从而预防中断。其次，优先投资模组化生产，以实现重组蛋白和疫苗生产之间的快速转换，缩短切换时间并最大限度地提高产能运转率。第三，积极与监管机构沟通，参与相关工作小组，儘早提交试点资料包，并设计符合不断变化的监管要求的临床和安全方案。

结合专家访谈、文献整合、专利和监管检验以及资料三角验证的多方面研究框架，确保了稳健且可操作的见解。

本分析基于多方法研究，整合了专家访谈、二手文献以及结构化资料的三角验证。主要资料来源包括对学术界、产业界和合约服务供应商(CSP) 的高级研发负责人、製造企业高管和监管专家的保密检验，这些访谈构成了情境建构的基础，并有助于检验新兴趋势。二手研究涵盖了同行评审文献、专利申请、监管指导文件和技术白皮书，旨在建立技术采纳和製造演进的科学和监管背景。

这份高层结论总结了综合科学创新、监管灵活性和营运韧性如何决定动物生物技术领域的长期成功。

总之，动物生物技术的发展离不开科学创新、供应链重组和监管调整的相互作用，这三者共同为市场参与企业创造了机会和挑战。细胞培养、基因工程和定序技术的进步带来了新的产品类型和效率提升，而关税趋势和区域政策变化则迫使企业重新评估其采购、生产和伙伴关係策略。能够将平台能力转化为可重复的生产流程、保持监管适应性并建立能够降低地缘政治和物流风险的弹性供应链网络的企业，才能最终取得成功。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：动物生物技术市场：依产品类型划分

  • 重组蛋白
    • 抗体
    • 酵素
      • 脂肪酶
      • 植酸酶
      • 蛋白酶
    • 生长激素
  • 疫苗
    • DNA疫苗
    • 灭活疫苗
    • 减毒活病毒疫苗
    • 次单位疫苗

第九章：动物生物技术市场：依技术划分

  • 细胞培养
    • 禽类细胞培养
    • 昆虫细胞培养
    • 哺乳动物细胞培养
  • 基因工程
    • 基因编辑
    • 基因合成
    • 基因改造技术
  • PCR和DNA定序
    • 次世代定序
    • PCR试剂盒
    • 桑格定序

第十章 动物生物技术市场：依应用领域划分

  • 诊断
    • ELISA试剂盒
    • 横向流动化验
    • 基于PCR的检测
  • 药物发现
    • 先导药物最适化
    • 临床前试验
    • 目标识别
  • 饲料添加剂
    • 碳水化合物消化酶
    • 植酸酶
    • 蛋白酶

第十一章 动物生物技术市场：依最终用户划分

  • 畜牧场
  • 合约研究机构
  • 製药公司
  • 研究机构

第十二章 动物生物技术市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：动物生物技术市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 动物生物技术市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国动物生物技术市场

第十六章：中国动物生物技术市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Animal Genetics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals plc
  • Elanco Animal Health Incorporated
  • Genus plc
  • Hendrix Genetics BV
  • HIPRA SA
  • IDEXX Laboratories, Inc.
  • Merck & Co., Inc.
  • Neogen Corporation
  • Phibro Animal Health Corporation
  • Recombinetics, Inc.
  • Thermo Fisher Scientific Inc.
  • Trans Ova Genetics, LC
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-437517DB6EAD

The Animal Biotechnology Market was valued at USD 33.81 billion in 2025 and is projected to grow to USD 36.49 billion in 2026, with a CAGR of 8.68%, reaching USD 60.56 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 33.81 billion
Estimated Year [2026] USD 36.49 billion
Forecast Year [2032] USD 60.56 billion
CAGR (%) 8.68%

A strategic orientation to animal biotechnology that frames scientific innovation, regulatory evolution, and supply chain resilience as core drivers of executive decision making

Animal biotechnology stands at an inflection point where advances in molecular tools, manufacturing platforms, and regulatory frameworks converge to redefine how animal health, nutrition, and research solutions are developed and deployed. The industry now spans recombinant proteins, vaccine innovation, precision feed additives, and diagnostics that support not only livestock productivity but also biomedical research and translational science. Investors, policy makers, and corporate leaders are increasingly focused on resilient value chains, accelerated development timelines, and technologies that reduce environmental footprint while enhancing animal welfare.

Emergent capabilities in gene editing, high-throughput sequencing, and advanced cell culture are enabling new classes of biologics and platform technologies whose downstream effects will extend across therapeutic development, diagnostic throughput, and farm-level adoption. At the same time, intensifying public scrutiny, evolving trade policies, and shifting procurement practices are prompting organizations to reassess sourcing strategies and regulatory readiness. This introduction frames the critical levers-technology, policy, supply chain, and commercial strategy-that executives must prioritize to convert scientific opportunity into sustainable competitive advantage across the animal biotechnology ecosystem.

How technological inflection points, evolving commercialization models, and regulatory adaptation are reshaping competitive dynamics in animal biotechnology

The landscape of animal biotechnology is undergoing transformative shifts driven by the maturation of platform technologies and evolving commercialization pathways. Gene editing tools and transgenic methodologies have moved from proof-of-concept stages to operational use cases that accelerate trait engineering and vaccine antigen design. Concurrently, improvements in cell culture systems-including avian, insect, and mammalian platforms-are enabling more scalable and cost-efficient biologics manufacturing that reduces dependence on legacy processes. These technological inflections are also complemented by advances in sequencing and diagnostics, where next-generation sequencing and improved PCR workflows are increasing analytic resolution and shortening time-to-result horizons.

Commercial models are also shifting: contract development and manufacturing organizations are expanding capabilities to offer end-to-end services, while partnerships between research laboratories and industry actors are becoming the norm to share risk and speed deployment. Regulatory authorities are adapting to new modalities with more iterative, science-based dialogues, while sustainability pressures are pushing firms to seek lower-emissions manufacturing footprints and alternative inputs. Together, these shifts are altering competitive dynamics and creating new pathways for organizations that can integrate platform technologies, agile regulatory strategies, and resilient supply models to capture emerging opportunities in animal biotechnology.

Understanding how 2025 tariff shifts are recalibrating supply chains, sourcing strategies, and operational risk frameworks across the animal biotechnology value chain

Tariff policy developments in the United States in 2025 are exerting cumulative effects on supply chain economics, sourcing strategies, and operational planning within the animal biotechnology sector. Increased import duties on reagents, laboratory equipment, and specialized components raise landed input costs and compress margins for manufacturers and service providers. Companies are responding by accelerating supplier diversification, securing longer-term contracts with non-U.S. vendors, and exploring near-shoring or reshoring options to mitigate exposure to tariff volatility. These changes have downstream implications for procurement cycles, inventory management, and capital allocation decisions.

Beyond immediate cost pressures, tariff-driven realignments influence strategic partnerships and R&D collaborations. Organizations that previously relied on cross-border exchanges for early-stage research materials may pivot toward domestic suppliers or broaden collaborative networks to include geographically diversified research partners. Regulatory compliance and customs processes have become more complex, increasing administrative overhead for cross-border shipments of biologics and diagnostic kits. As a result, firms are investing in supply chain visibility tools and dual-sourcing strategies to maintain continuity. In parallel, the tariff environment is prompting some stakeholders to accelerate investments in local manufacturing capacity, which can reduce tariff exposure but requires careful consideration of workforce availability, capital intensity, and regulatory approvals. Overall, the tariff landscape is driving a recalibration of risk frameworks and operational models that will influence strategic planning for the foreseeable future.

Detailed segmentation analysis revealing how product, technology, application, and end-user distinctions determine development priorities, go-to-market models, and investment focus

Segmentation dynamics reveal distinct pathways to value and operational priorities across product types, technologies, applications, and end users. Based on product type, the sector spans recombinant proteins and vaccines; recombinant proteins include antibodies, enzymes, and growth hormones, and the enzymes subset comprises lipases, phytases, and proteases, while vaccines encompass DNA vaccines, inactivated vaccines, live attenuated vaccines, and subunit vaccines. This diversity requires differentiated development strategies: antibodies prioritize specificity and manufacturing scale, enzymes emphasize thermostability and feed integration, and vaccine modalities demand tailored cold-chain and regulatory approaches.

Based on technology, the market includes cell culture, genetic engineering, and PCR and DNA sequencing; cell culture further breaks down into avian, insect, and mammalian cell culture, genetic engineering covers gene editing, gene synthesis, and transgenic technology, while PCR and DNA sequencing span next-generation sequencing, PCR kits, and Sanger sequencing. These technological axes shape capital intensity, talent requirements, and regulatory interfaces. Based on application, the landscape includes diagnostics, drug discovery, and feed additives; diagnostics subdivide into ELISA kits, lateral flow assays, and PCR-based tests, drug discovery covers lead optimization, preclinical testing, and target identification, and feed additives include carbohydrases, phytases, and proteases. Application-driven segmentation highlights where value accrues: diagnostics deliver recurrent consumable demand, drug discovery requires extended R&D investment, and feed additives emphasize agricultural integration. Based on end-user, demand is sourced from animal farms, contract research organizations, pharmaceutical companies, and research laboratories. Each end-user presents unique procurement patterns and service-level expectations, requiring vendors to align product design, regulatory support, and commercial models to end-user priorities and operational constraints.

Comparative regional intelligence demonstrating how Americas, Europe Middle East and Africa, and Asia-Pacific dynamics influence regulatory strategy, manufacturing, and adoption trajectories

Regional dynamics shape opportunity sets, regulatory contours, and adoption trajectories across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, established research infrastructure and significant private investment foster rapid adoption of novel biologics and diagnostic platforms, while logistical hubs and advanced manufacturing clusters support contract development and manufacturing activity. North American regulatory dialogues increasingly emphasize harmonization and expedited pathways for innovative modalities, creating an environment where scale-up and commercial launch can proceed with greater predictability when regulatory strategies are proactively managed.

In Europe, the Middle East and Africa, regulatory diversity and complex cross-border trade arrangements require granular regulatory intelligence and adaptable supply chains. The region combines mature scientific centers with markets that are still developing capacity for advanced biologics, making partnerships and public-private initiatives particularly valuable. Policy priorities around animal welfare and sustainability often shape procurement preferences in this region. In the Asia-Pacific, a combination of rapid market growth, expanding domestic manufacturing capability, and increasing public research funding is accelerating adoption of vaccines, feed additives, and diagnostics. Local manufacturers and research institutions are scaling capabilities in cell culture and genetic engineering, and cross-border collaborations are common as firms leverage cost-competitive production while accessing large regional demand pools. Across all regions, firms that craft localized regulatory strategies and supply chain architectures will gain an edge in commercial execution.

How corporate strategies combining vertical integration, platform differentiation, and talent prioritization are determining competitive positioning in animal biotechnology

Company strategies in animal biotechnology are converging on several repeatable patterns that signal winners and pressure points across the competitive landscape. Leading actors are pursuing vertical integration and strategic partnerships to secure critical inputs, reduce time-to-market, and expand value-added service offerings. Contract development and manufacturing organizations are investing in platform flexibility to accommodate both recombinant proteins and vaccine modalities, enabling them to capture a broader share of outsourced development and production demand. At the same time, specialist technology providers are differentiating through proprietary cell lines, optimized fermentation processes, or unique sequencing and diagnostic chemistries that deliver performance advantages for specific end-users.

Investment profiles show a balance between R&D intensity for next-generation modalities and operational investments in scale, quality systems, and regulatory affairs. Talent acquisition and retention have emerged as key competitive factors, with companies prioritizing cross-disciplinary teams that combine molecular biology expertise with regulatory, manufacturing, and commercialization experience. Strategic M&A and licensing transactions are being used to access niche technologies or expand geographic reach, while alliances between academic institutions and commercial developers accelerate translational milestones. Overall, organizations that combine platform innovation with robust regulatory roadmaps and flexible manufacturing partnerships are best positioned to capture emerging opportunities across animal health, feed solutions, and diagnostic applications.

Actionable strategies for leaders to fortify supply chains, modularize manufacturing, engage regulators proactively, and accelerate platform-based innovation for commercial scalability

Industry leaders should adopt a suite of tangible actions to convert scientific capability into durable commercial advantage. First, diversify procurement and logistics by qualifying multiple suppliers across geographies, establishing strategic inventory buffers for critical reagents, and investing in supply chain visibility systems to anticipate disruptions. Second, prioritize modular manufacturing investments that allow rapid reconfiguration between recombinant proteins and vaccine production, reducing changeover time and maximizing capacity utilization. Third, commit to proactive regulatory engagement by participating in jurisdictional working groups, submitting pilot data packages early, and designing clinical and safety programs that align with evolving agency expectations.

Fourth, accelerate platform-based innovation by standardizing analytical methods, sharing validated cell lines or assay formats where permissible, and pursuing partnerships that co-fund translational milestones. Fifth, enhance commercial adoption through end-user education programs that demonstrate product efficacy, ease of use, and return on operational metrics for animal farms and research laboratories. Sixth, manage talent risk through targeted recruitment, professional development, and cross-functional governance that ensures continuity across R&D, manufacturing, and regulatory teams. Implementing these recommendations will enable organizations to mitigate near-term policy headwinds, optimize capital deployment, and build scalable operations aligned with long-term scientific and commercial objectives.

A multi-method research framework combining expert interviews, literature synthesis, patent and regulatory review, and data triangulation to ensure robust and actionable insights

This analysis is based on a multi-method research approach that integrates primary expert engagement, secondary literature synthesis, and structured data triangulation. Primary inputs included confidential interviews with senior R&D leaders, manufacturing executives, and regulatory specialists across academia, industry, and contract service providers; these interviews informed scenario development and validated emergent trends. Secondary research encompassed peer-reviewed literature, patent filings, regulatory guidance documents, and technical white papers to establish the scientific and regulatory context for technology adoption and manufacturing evolution.

Quantitative and qualitative findings were cross-checked through triangulation to reconcile divergent perspectives and to highlight consensus areas. The research process also included value-chain mapping exercises to identify critical bottlenecks in sourcing, production, and distribution, and a review of public procurement and policy developments to assess potential commercial implications. Quality assurance measures included independent peer review by domain experts, source transparency protocols, and iterative feedback loops with subject-matter specialists to ensure robustness and relevance of conclusions.

Executive conclusion summarizing how integrated scientific innovation, regulatory agility, and operational resilience will determine long-term success within animal biotechnology

In conclusion, animal biotechnology is evolving through an interplay of scientific innovation, supply chain realignment, and regulatory adaptation that together create both opportunity and complexity for market participants. Technological advances in cell culture, genetic engineering, and sequencing are unlocking new product classes and efficiencies, while tariff dynamics and regional policy shifts are forcing organizations to reassess sourcing, manufacturing, and partnership strategies. Successful players will be those that translate platform capabilities into reproducible manufacturing processes, maintain regulatory agility, and construct resilient supply networks that mitigate geopolitical and logistical risks.

Looking ahead, the ability to synthesize scientific rigor with operational excellence will determine which organizations capture sustained value. Firms that invest in modular manufacturing, cultivate diversified supplier ecosystems, and engage proactively with regulators will be better positioned to convert R&D breakthroughs into scalable products and services. The path forward requires a balance of innovation, disciplined execution, and strategic partnerships that together will drive long-term growth and impact across animal health, nutrition, and research domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Biotechnology Market, by Product Type

  • 8.1. Recombinant Proteins
    • 8.1.1. Antibodies
    • 8.1.2. Enzymes
      • 8.1.2.1. Lipases
      • 8.1.2.2. Phytases
      • 8.1.2.3. Proteases
    • 8.1.3. Growth Hormones
  • 8.2. Vaccines
    • 8.2.1. DNA Vaccines
    • 8.2.2. Inactivated Vaccines
    • 8.2.3. Live Attenuated Vaccines
    • 8.2.4. Subunit Vaccines

9. Animal Biotechnology Market, by Technology

  • 9.1. Cell Culture
    • 9.1.1. Avian Cell Culture
    • 9.1.2. Insect Cell Culture
    • 9.1.3. Mammalian Cell Culture
  • 9.2. Genetic Engineering
    • 9.2.1. Gene Editing
    • 9.2.2. Gene Synthesis
    • 9.2.3. Transgenic Technology
  • 9.3. PCR And DNA Sequencing
    • 9.3.1. Next-Generation Sequencing
    • 9.3.2. PCR Kits
    • 9.3.3. Sanger Sequencing

10. Animal Biotechnology Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. ELISA Kits
    • 10.1.2. Lateral Flow Assays
    • 10.1.3. PCR-Based Tests
  • 10.2. Drug Discovery
    • 10.2.1. Lead Optimization
    • 10.2.2. Preclinical Testing
    • 10.2.3. Target Identification
  • 10.3. Feed Additives
    • 10.3.1. Carbohydrases
    • 10.3.2. Phytases
    • 10.3.3. Proteases

11. Animal Biotechnology Market, by End-User

  • 11.1. Animal Farms
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Laboratories

12. Animal Biotechnology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Biotechnology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Biotechnology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Animal Biotechnology Market

16. China Animal Biotechnology Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Animal Genetics, Inc.
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. Biogenesis Bago S.A.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Ceva Sante Animale S.A.
  • 17.10. Dechra Pharmaceuticals plc
  • 17.11. Elanco Animal Health Incorporated
  • 17.12. Genus plc
  • 17.13. Hendrix Genetics BV
  • 17.14. HIPRA S.A.
  • 17.15. IDEXX Laboratories, Inc.
  • 17.16. Merck & Co., Inc.
  • 17.17. Neogen Corporation
  • 17.18. Phibro Animal Health Corporation
  • 17.19. Recombinetics, Inc.
  • 17.20. Thermo Fisher Scientific Inc.
  • 17.21. Trans Ova Genetics, LC
  • 17.22. Vetoquinol S.A.
  • 17.23. Virbac S.A.
  • 17.24. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL BIOTECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANIMAL BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANIMAL BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 263. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 267. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 268. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 270. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 271. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 272. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 274. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 276. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 299. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 300. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 301. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 302. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 303. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 304. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 305. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 306. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 308. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 309. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 310. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 311. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 312. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 313. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 314. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 316. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 317. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 318. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 319. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 320. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2032 (USD MILLION)
  • TABLE 322. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2032 (USD MILLION)
  • TABLE 323. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 324. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 325. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 326. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 327. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUEN